Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
GSK233705 + GW642444
- Development stage
- Phase 2
- Lead developer
- GSK
- Modality
- Small Molecules
- Administration
- Inhalation
01
Overview
GSK233705 + GW642444 is an investigational fixed-dose combination of two inhaled bronchodilators developed for the treatment of chronic obstructive pulmonary disease (COPD). GSK233705 is a long-acting muscarinic antagonist (LAMA), while GW642444 is a long-acting beta2-adrenoceptor agonist (LABA). The combination aims to provide enhanced bronchodilation by targeting two complementary pathways involved in airway smooth muscle relaxation, potentially improving lung function and symptom control in COPD patients. Both agents have been studied individually and together in clinical trials, including studies assessing safety, pharmacokinetics, and efficacy in healthy subjects and patients with COPD. The developer is GSK[1][2][4][5].
02
Targets
CHRM3 (M3)ADRB2 (β2)
Beyond the preview
Go deeper on GSK233705 + GW642444.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on GSK233705 + GW642444.